Publications
Scientific Manuscripts
ACCELERATE scientific manuscripts
2025
2024
2023
2022
2021
2020
5th ACCELERATE Paediatric Strategy Forum in collaboration with the European Medicines Agency and with the participation of the Food and Drug Administration: Medicinal product development of epigenetic modifiers for children
Paerson et al., European Journal of Cancer November 2020; 139:135-148
4th ACCELERATE Paediatric Strategy Forum in collaboration with the European Medicines Agency and with the participation of the Food and Drug Administration: Medicinal product development for acute myeloid leukaemia in children and adolescents
Pearson et al., European Journal of Cancer, European Journal of Cancer September 2020; 136:116-129
The RACE to accelerate drug development for children with cancer
The Lancet Child & Adolescent Health
Pearson, A. et al.
August 2020
2015-2019
Other relevant manuscripts
Other relevant publications section contain articles from the childhood cancer community which concern ACCELERATE. Various publications can be found here which are relevant to ACCELERATEs mission and/or childhood cancer patient drug development, etc.
Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)
Ferrari, A. et al., 2021. ESMO OPEN
Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to EMA and US FDA
Reaman, G., Karres D. et al., JCO, September 2020
ACCELERATE Platform
Annual Work Plan
Executive Summaries
Abbreviations
ALK: anaplastic lymphoma kinase
BPCA: Biologics Price Competition & Innovation
CDDF: Cancer Drug Development Forum
EMA: European Medicines Agency
ENCCA: European Network for Cancer Research in Children and Adolescents
FDA: Food and Drug Agency
IMI: Innovative Medicine Initiative
ITCC: Innovative Therapies for Children with Cancer
LTFU: long-term follow-up
MA: marketing authorisation
MoA: Mechanism of Action
PDCO: Paediatric Committee [of the EMA]
PIP: Paediatric Investigation Plan
PK: pharmacokinetic
PPoC: paediatric proof of concept
PREA: Pediatric Research Equity Act
PRINTO: Paediatric Rheumatology International Trials Organisation
SIOPE: European Society for Paediatric Oncology
US[A]: United States [of America]
TYA: teenagers and young adults
WG: Working Group
WR: written requests